{
    "cancer_info": {
        "cancer_name": "Uterine Neoplasms"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "History and physical exam (including pelvic exam)",
            "CBC",
            "Liver function tests",
            "Renal function tests",
            "CA-125 (if elevated initially or serous histology)",
            "Pelvic MRI (preferred for local extent)",
            "CT of chest, abdomen, and pelvis",
            "FDG-PET/CT (for suspected metastasis)",
            "Transvaginal ultrasound (if MRI contraindicated)",
            "Endometrial biopsy/D&C with expert review",
            "Cervical biopsy (if cervical involvement suspected)",
            "Peritoneal washings for cytology",
            "Sentinel lymph node mapping",
            "Omental biopsy",
            "Lymph node assessment (SLN algorithm or lymphadenectomy)",
            "IHC panel for sarcoma subtyping (CD10, cyclin D1, BCOR, desmin, SMA, HMB45, melanA, myogenin, MyoD1)",
            "Molecular tests: FISH/RNAseq for gene fusions (JAZF1, SUZ12, PHF1, EPC1, YWHAE, FAM22, BCOR, SMARCA4, FOXO1)",
            "Universal MMR/MSI testing",
            "p53 IHC",
            "POLE mutation testing",
            "HER2 IHC ± FISH (for serous/carcinosarcoma or p53-aberrant tumors)",
            "ER/PR testing (for Stage III/IV/recurrent disease or sarcomas)",
            "TMB testing",
            "NTRK fusion testing",
            "ALK fusion testing (for inflammatory myofibroblastic tumors)"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Stage I (Endometrial Carcinoma)",
            "risk_group": "Low risk (Stage IA G1-2, no LVSI)",
            "treatment_plans": [
                {
                    "treatment_line": "Adjuvant Therapy",
                    "patient_subgroup": "Low risk",
                    "plan_name": "Observation",
                    "plan_details": "No adjuvant therapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage I (Endometrial Carcinoma)",
            "risk_group": "Intermediate risk (Stage IA G3 or IB G1-2)",
            "treatment_plans": [
                {
                    "treatment_line": "Adjuvant Therapy",
                    "patient_subgroup": "Intermediate risk",
                    "plan_name": "Vaginal brachytherapy",
                    "plan_details": "Vaginal cuff brachytherapy: 6 Gy × 5 fractions or 7 Gy × 3 fractions",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage I-II (Endometrial Carcinoma)",
            "risk_group": "High-intermediate risk (IB G3, Stage II, or age ≥60 with LVSI/deep invasion)",
            "treatment_plans": [
                {
                    "treatment_line": "Adjuvant Therapy",
                    "patient_subgroup": "High-intermediate risk",
                    "plan_name": "EBRT ± brachytherapy ± systemic therapy",
                    "plan_details": "External beam radiotherapy (45-50 Gy) ± vaginal brachytherapy ± carboplatin/paclitaxel",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Appropriate"
                }
            ]
        },
        {
            "staging_criteria": "Stage III-IV (Endometrial Carcinoma)",
            "risk_group": "High risk (serous/clear cell/carcinosarcoma)",
            "treatment_plans": [
                {
                    "treatment_line": "Primary Treatment",
                    "patient_subgroup": "Resectable disease",
                    "plan_name": "Maximal cytoreduction",
                    "plan_details": "Total hysterectomy with BSO + surgical staging",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Adjuvant Therapy",
                    "patient_subgroup": "Stage III-IV",
                    "plan_name": "Systemic therapy + EBRT/brachytherapy",
                    "plan_details": "Carboplatin AUC 5-6 + paclitaxel 175mg/m2 ± pembrolizumab (for dMMR/MSI-H) ± trastuzumab (for HER2+)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Recurrent/Metastatic (Endometrial Carcinoma)",
            "risk_group": "Recurrent disease",
            "treatment_plans": [
                {
                    "treatment_line": "First-Line",
                    "patient_subgroup": "No prior systemic therapy",
                    "plan_name": "Carboplatin/paclitaxel",
                    "plan_details": "Carboplatin AUC 5-6 + paclitaxel 175mg/m2",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-Line",
                    "patient_subgroup": "dMMR/MSI-H",
                    "plan_name": "Pembrolizumab/dostarlimab + chemotherapy",
                    "plan_details": "Pembrolizumab 200mg IV Q3W or dostarlimab + carboplatin/paclitaxel",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Second-Line",
                    "patient_subgroup": "pMMR tumors",
                    "plan_name": "Lenvatinib + pembrolizumab",
                    "plan_details": "Lenvatinib 20mg daily + pembrolizumab 200mg IV Q3W",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Biomarker-Directed",
                    "patient_subgroup": "NTRK fusion-positive",
                    "plan_name": "TRK inhibitors",
                    "plan_details": "Larotrectinib 100mg BID or entrectinib 600mg daily",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Appropriate"
                }
            ]
        },
        {
            "staging_criteria": "Low-grade ESS/Adenosarcoma",
            "risk_group": "Stage I (favorable prognosis)",
            "treatment_plans": [
                {
                    "treatment_line": "Primary Treatment",
                    "patient_subgroup": "Localized disease",
                    "plan_name": "Surgery ± anti-estrogen therapy",
                    "plan_details": "Total hysterectomy ± BSO + aromatase inhibitors (e.g., letrozole 2.5mg daily)",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Appropriate"
                }
            ]
        },
        {
            "staging_criteria": "High-grade Sarcomas (LMS, HG-ESS, UUS)",
            "risk_group": "Stages II-IV (poor prognosis)",
            "treatment_plans": [
                {
                    "treatment_line": "Primary Treatment",
                    "patient_subgroup": "Resectable disease",
                    "plan_name": "En bloc resection",
                    "plan_details": "Total hysterectomy ± BSO without morcellation",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Systemic Therapy",
                    "patient_subgroup": "Advanced disease",
                    "plan_name": "Doxorubicin-based regimens",
                    "plan_details": "Doxorubicin 60mg/m2 ± ifosfamide",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Later-Line",
                    "patient_subgroup": "Post-anthracycline progression",
                    "plan_name": "Trabectedin",
                    "plan_details": "Trabectedin 1.5mg/m2 IV over 24 hours Q3W",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Appropriate"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "MMR/MSI-H: Predicts response to immunotherapy (pembrolizumab/dostarlimab); p53 aberrant: Poor prognosis, mandates HER2 testing; POLE mutations: Favorable prognosis allowing therapy de-escalation; HER2 overexpression: Trastuzumab benefit in serous carcinoma/carcinosarcoma; TMB-H (≥10 mut/Mb): Pembrolizumab eligibility; NTRK fusions: Targetable with larotrectinib/entrectinib; ER/PR expression: Guides hormonal therapy in sarcomas; JAZF1-SUZ12 fusion (LG-ESS): Indolent behavior; YWHAE-NUTM2 fusion (HG-ESS): Aggressive phenotype; TSC1/TSC2 mutations (PEComa): mTOR inhibitor response"
    },
    "guideline_id": "（2025.V2）NCCN临床实践指南：子宫肿瘤.txt"
}